Screener
UroGen Pharma URGN Business Segments — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of revenue | 6,572 | 3,550 | 10,711 | 5,880 |
| Gross profit | 65,884 | 20,665 | 112,704 | 38,589 |
| Operating expenses: | ||||
| Research and development expenses | 17,336 | 18,914 | 32,933 | 38,785 |
| Selling, general and administrative expenses | 48,437 | 43,199 | 99,923 | 78,166 |
| Operating income (loss) | 111 | (41,448) | (20,152) | (78,362) |
| Financing on prepaid forward obligation | (4,545) | (4,644) | (9,051) | (9,227) |
| Interest expense on long-term debt | (4,887) | (4,132) | (9,072) | (8,200) |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's business segments — research and development expense?
- UroGen Pharma (URGN) reported business segments — research and development expense of $17.34M in Q2 2026.
- What does business segments — research and development expense mean?
- This metric represents the total expenditure dedicated to the discovery, development, and clinical testing of new pharmaceutical products and technologies. It is the primary indicator of the company's investment in its future revenue-generating assets and long-term competitive position. Investors use this to gauge the intensity of the company's innovation efforts relative to its clinical milestones.
Ask your AI about UroGen Pharma's business segments — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude